Vertex Pharma (VRTX) Misses Q1 EPS by 20c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $523.93 -2.1%
Revenue Growth %: +10.7%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +10.7%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.06, $0.20 worse than the analyst estimate of $4.26. Revenue for the quarter came in at $2.77 billion versus the consensus estimate of $2.86 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.85-12 billion, versus the consensus of $11.982 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
- Northrop Grumman wins $43.8M Navy contract for Trident II facility
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
